Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
supporting study
Study period:
During November 1979
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1979

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Version / remarks:
Conducted prior to adoption of OECD 401.
Deviations:
yes
Remarks:
Short acclimatisation period, wide variation in starting body weights, only 5 animals/sex.
Principles of method if other than guideline:
Method: other: Hazleton protocol (number P631/22/4/-/553/d/rev.1). The first four doses were in effect a dose-range finding study (only deaths recorded for 48 hours) and the highest dose a limit test.
GLP compliance:
no
Test type:
standard acute method
Limit test:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
[[(phosphonomethyl)imino]bis[(ethylenenitrilo)bis(methylene)]]tetrakisphosphonic acid, sodium salt
EC Number:
244-751-4
EC Name:
[[(phosphonomethyl)imino]bis[(ethylenenitrilo)bis(methylene)]]tetrakisphosphonic acid, sodium salt
Cas Number:
22042-96-2
Molecular formula:
C9H28N3O15P5.xNa
IUPAC Name:
sodium hydrogen [10,10-dihydroxy-10-oxido-2,5,8-tris(phosphonomethyl)-2,5,8-triaza-10-phosphadec-1-yl]phosphonate
Constituent 2
Reference substance name:
[[(phosphonomethyl)imino]bis[(ethylenenitrilo)bis(methylene)]]tetrakisphos phonic acid, sodium salt
IUPAC Name:
[[(phosphonomethyl)imino]bis[(ethylenenitrilo)bis(methylene)]]tetrakisphos phonic acid, sodium salt
Test material form:
liquid

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Bantin and Kingman Ltd
- Age at study initiation: No data
- Weight at study initiation: 150 to 250 g
- Fasting period before study: Overnight (18-20 hours)
- Housing: Groups of 2 or 5 in solid-bottomed plastic cages.
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: At least three days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25
- Humidity (%): 40-60
- Air changes (per hr): No data
- Photoperiod (hrs dark / hrs light): Natural light supplemented with fluorescent lighting during working hours (08.45-17.00)


IN-LIFE DATES: No data

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Details on oral exposure:
VEHICLE
- Concentration in vehicle: 25, 50, 100, 200, 500 mg/ml
- Justification for choice of vehicle: None given


MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg
Doses:
250, 500, 1000, 2000 and 5000 mg/kg bw. Doses presumed to be given in terms of DTPMP-xNa (not diluted solution), but not to have been corrected for purity, therefore presumed equivalent to 82.5, 165, 330, 660, and 1650 mg active salt/kg bw respectively.
No. of animals per sex per dose:
Two (except five at 500 mg/kg bw)
Control animals:
no
Details on study design:
- Duration of observation period following administration: High dose group only: 14 days
- Frequency of observations and weighing: High dose group only: All animals were observed for overt signs of toxicity or behavioural change at 15 minutes, 1, 2, and 4 hours after treatment and subsequently once daily for 14 days. Individual body weights were recorded on the day before treatment, on the day of treatment and 14 days after treatment.
- Necropsy of survivors performed: yes, in high dose group only.
- Other examinations performed: gross pathology.
Statistics:
None

Results and discussion

Effect levelsopen allclose all
Sex:
male/female
Dose descriptor:
LD50
Effect level:
>= 5 000 mg/kg bw
Sex:
male/female
Dose descriptor:
LD50
Effect level:
>= 1 650 mg/kg bw
Based on:
act. ingr.
Remarks:
active salt
Remarks on result:
other: equivalent to 1303 mg active acid/kg bw
Mortality:
No animals died during the observation period.
Clinical signs:
other: No clinical signs.
Gross pathology:
No animals died so no necropsies were performed.
Other findings:
None reported.

Any other information on results incl. tables

Calculation of equivalent dose: Based on DTPMP-xNa composed of 33% active salt including minor components, remainder water (MSDS).

For purposes of comparison with other Group 3 results, 
1650 mg active salt/kg bw is equivalent to 1303 mg parent acid (DTPMP, CAS 15827-60-8)/kg bw.

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Remarks:
No mortality or clinical signs of toxicity occurred in any of the test animals.
Conclusions:
In an acute oral toxicity study, conducted prior to the adoption of OECD Test Guidelines and GLP, the LD50 for DTPMP-xNa was ≥5000 mg/kg bw (equivalent to ≥1650 mg active salt/kg bw and ≥1303 mg active acid/kg bw) in the rat.